For immediate release: November 29, 2004
Vancouver, BC and Bridgewater, NJ - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) and Enzon Pharmaceuticals Inc. ("ENZON"; NASDAQ: ENZN) announced today a conference call and webcast will be held on Wednesday, December 1, 2004 after the completion of the Oncologic Drugs Advisory Committee (ODAC) meeting on MARQIBO™.
The companies will issue a news release as soon as possible after the conclusion of the ODAC meeting. The conference call will take place after the news release is distributed. The conference call is anticipated to begin at 6:00 pm EST (3:00 pm PST).
About the Conference Call
To participate in the conference call, please dial 1-877-211-7911. The call will be available for replay until December 8, 2004 by calling 1-800-408-3053 and entering the pass code 3115637#.
The live or archived webcast can be accessed through the companies’ websites at www.inexpharm.com or www.enzon.com.
About INEX
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about INEX and this news release can be found at www.inexpharm.com.
About ENZON
Enzon Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. Further information about ENZON and this news release can be found at www.enzon.com.
Contacts for Inex Pharmaceuticals Corporation
Investors
Ian Mortimer
Senior Director, Investor Relations
Phone: 604-419-3200
Media
Miriam Zitner
James Hoggan & Associates Inc.
Phone: 604-739-7500
Contacts for Enzon Pharmaceuticals, Inc.
Investors
Susan M. Mesco
Director, Investor Relations
Phone: 908-541-8678
Media
Mark Vincent
Euro RSCG Life NRP
Phone: 212-845-4239
INEX’s common shares are traded on the Toronto Stock Exchange under the trading symbol “IEX”.
ENZON’s common shares are traded on NASDAQ under the trading symbol “ENZN”.
